DEF: Movano Seeks Reverse Stock Split, Share Increase Amid Nasdaq Delisting Threat

Movano Inc. will hold its 2025 annual meeting to vote on a new reverse stock split, a significant increase in authorized shares, and auditor ratification, as it faces Nasdaq delisting for low stock price and late filing.

Summary

• Stockholders will vote on the election of two Class I directors, Emily Wang Fairbairn and Michael Leabman, for three-year terms.
• A proposal to amend the Certificate of Incorporation for a reverse stock split at ratios between 1-for-2 and 1-for-15 will be voted on, with the Board having discretion to choose the ratio within one year.
• The company seeks to increase authorized common stock from 500,000,000 to 2,000,000,000 shares to provide flexibility for future financings, acquisitions, and equity compensation.
• Stockholders will ratify the appointment of RBSM LLP as the independent registered public accounting firm for 2025, following the resignation of previous auditor Moss Adams LLP.
• The company received a Nasdaq notice on July 7, 2025, for non-compliance with the $1.00 minimum bid price rule and for the late filing of its Form 10-Q for the quarter ended March 31, 2025.
• A previous 1-for-15 reverse stock split, effective October 29, 2024, failed to sustain the company's compliance with Nasdaq's minimum bid price requirement.

Sentiment

Score: 3

Explanation: The filing highlights significant challenges, including repeated Nasdaq non-compliance, the failure of a previous reverse stock split, and material weaknesses in internal controls. While management is taking steps to address these issues and explore strategic alternatives, the underlying operational and financial performance appears weak, leading to a low sentiment score. The potential for significant dilution from increased authorized shares also weighs negatively.

Positives

• The Board is actively addressing Nasdaq listing compliance issues by proposing another reverse stock split.
• The company is exploring strategic alternatives, including a sale or merger, to maximize shareholder value.
• The Board maintains an independent chairperson, Emily Wang Fairbairn, ensuring objective oversight.
• Executive compensation is structured to emphasize long-term equity, aligning management interests with stockholders.
• The Board comprises experienced individuals with diverse backgrounds in finance, technology, and medical devices.

Negatives

• Received a Nasdaq notice of non-compliance due to the common stock falling below $1.00 per share for 30 consecutive trading days.
• Received a Nasdaq notice of non-compliance for the delayed filing of the Form 10-Q for the quarter ended March 31, 2025.
• A prior 1-for-15 reverse stock split in October 2024 failed to sustain Nasdaq compliance, necessitating another reverse stock split proposal.
• The company is not eligible for a standard compliance period due to the recent reverse stock split, leading to a Nasdaq delisting determination.
• The proposed increase in authorized shares from 500,000,000 to 2,000,000,000 could lead to significant dilution for existing shareholders.
• Moss Adams LLP, the previous independent registered public accounting firm, resigned on June 24, 2025.
• Material weaknesses in internal controls over financial reporting were disclosed for the fiscal years ended December 31, 2024, and 2023.

Risks

• A reverse stock split may not increase the price of common stock over the long-term or proportionally, as demonstrated by the failure of the 2024 split to sustain compliance.
• A reverse stock split may decrease the liquidity of common stock due to a reduced number of issued shares and potentially fewer market makers.
• Stockholders may own 'odd lots' (less than 100 shares) after a reverse stock split, which can result in incrementally higher trading costs.
• A reverse stock split may be viewed negatively by the market, potentially leading to a decrease in overall market capitalization.
• Failure to approve the reverse stock split proposal could expose the company to delisting from The Nasdaq Capital Market.
• Future issuance of additional authorized shares, if Proposal 3 is approved, may dilute the earnings per share and the equity and voting rights of existing stockholders.
• Material weaknesses in internal controls over financial reporting (ineffective control environment, IT general controls, process-level controls, financial close and reporting controls) could impact the reliability of financial reporting.

Future Outlook

The Board has initiated a process to explore strategic alternatives, including a sale, merger, or similar transaction, to maximize shareholder value. The proposed increase in authorized shares is intended to provide flexibility for future financings, strategic acquisitions, and equity compensation. The Board intends to implement a reverse stock split on or before October 17, 2025, or a later date determined by Nasdaq, to regain compliance with the Minimum Bid Price Requirement.

Management Comments

• "We look forward to your participation in the annual meeting by attending via remote communications or by submitting your proxy."
• "The Board believes that proposing multiple reverse stock split ratios by the Reverse Stock Split Proposal provides us with the most flexibility to achieve the desired results of the Reverse Stock Split Proposal."
• "We believe that the Reverse Stock Split Certificate of Incorporation Amendment is our best option to meet the criteria to satisfy the minimum per share bid price requirement for continued listing on The Nasdaq Capital Market."
• "We believe increasing the trading price of our Common Stock may also assist in our capital-raising efforts by making our Common Stock more attractive to a broader range of investors and promote greater liquidity for our stockholders."
• "The Board intends to implement an amendment to the Certificate of Incorporation effecting a reverse stock split at one of the reverse stock split ratios set forth in the Reverse Stock Split Certificate of Incorporation Amendment only if it believes that a decrease in the number of issued shares of Common Stock is in the best interests of the Company and our stockholders and is likely to improve the trading price of our Common Stock and improve the likelihood that we will be allowed to maintain our listing on The Nasdaq Capital Market."
• "We do not currently have any definitive agreements to issue any of the proposed additional authorized shares of Common Stock that will become available for issuance if this Proposal 3 is approved by our stockholders and the Certificate of Amendment is effected. However, we are at all times investigating additional sources of financing which our Board believes will be in our best interests and in the best interests of our stockholders."

Industry Context

The company operates in an industry where maintaining public listing status and access to capital markets is crucial for growth and innovation. The repeated need for reverse stock splits and increased authorized shares suggests significant challenges in maintaining investor confidence and stock valuation, which is not uncommon for smaller, growth-oriented technology or medical device companies. The exploration of strategic alternatives indicates a potential shift in the company's long-term strategy, possibly seeking a larger partner or a different path to value creation in a competitive and capital-intensive medical device market, particularly in diabetes monitoring.

Comparison to Industry Standards

• The repeated necessity for reverse stock splits to maintain Nasdaq listing indicates a struggle to meet basic market capitalization and share price thresholds, which is below the standard for stable, established companies in the industry.
• The disclosure of material weaknesses in internal controls and the resignation of the previous auditor are significant governance concerns, suggesting a lack of robust financial oversight compared to industry best practices.
• The exploration of strategic alternatives (e.g., sale, merger) is a common strategy for companies facing valuation challenges or seeking to accelerate growth or market access, aligning with broader industry trends for smaller players in competitive sectors.
• The executive compensation structure, which emphasizes long-term equity, is a common practice to align management incentives with shareholder interests, consistent with general industry standards.

Corporate Governance

Legal Proceedings

• The company received a Nasdaq Delisting Determination due to non-compliance with the $1.00 Minimum Bid Price Rule and late filing of its Form 10-Q. The company has requested a hearing before a Nasdaq Hearings Panel to appeal this determination.

Related Party Transactions

• Certain directors and executive officers participated in the January 2023 Offering, purchasing common stock and warrants. Participants included J. Cogan ($25,000), Brian Cullinan ($10,000), Emily Wang Fairbairn ($250,000), Nan Kirsten Forte ($10,000), Michael Leabman ($25,000), and John Mastrototaro ($10,000).
• Certain directors and executive officers participated in the June 2023 Offering, purchasing common stock. Participants included J. Cogan ($35,000), Brian Cullinan ($10,000), Emily Wang Fairbairn ($250,000), Michael Leabman ($25,000), and John Mastrototaro ($20,000).
• Certain directors and executive officers participated in the November 2023 Offering, purchasing common stock. Participants included J. Cogan ($10,200), Emily Wang Fairbairn ($250,750), and John Mastrototaro ($10,200).
• Certain directors and executive officers participated in the April 2024 Private Placement, purchasing units consisting of common stock/pre-funded warrants and warrants. Participants included J. Cogan ($25,425), Ruben Caballero ($12,500), Brian Cullinan ($24,860), and John Mastrototaro ($99,723).
• Emily Wang Fairbairn and Malcolm Fairbairn (a 5% stockholder) are trustees of the Malcolm P. Fairbairn and Emily T. Fairbairn Charitable Remainder Unitrust, which holds shares and warrants of the company.

Stakeholder Impact

• Shareholders face potential significant dilution if the proposal to increase authorized shares is approved and new shares are issued, and risk of delisting if the reverse stock split fails to maintain Nasdaq compliance.
• Shareholders may experience increased transaction costs if they hold 'odd lots' of shares after a reverse stock split.
• The exploration of strategic alternatives could lead to a positive outcome for shareholders (e.g., acquisition premium) or further uncertainty regarding the company's future.
• Employees, particularly those with equity compensation, may see the value of their holdings impacted by stock price volatility and potential dilution.
• The identified material weaknesses in internal controls could impact investor confidence and the company's ability to attract future capital.

Next Steps

• Hold the 2025 Annual Meeting of Stockholders on September 26, 2025, to vote on the proposed resolutions.
• If approved, the Board will determine the specific reverse stock split ratio (between 1-for-2 and 1-for-15) and implement it on or prior to the one-year anniversary of the annual meeting, with an intent to do so by October 17, 2025, to regain Nasdaq compliance.
• If approved, the Board will file the Certificate of Amendment to increase authorized shares.
• Announce voting results in a Current Report on Form 8-K filed with the SEC within four business days following the Annual Meeting.
• Continue to appeal the Nasdaq Delisting Determination before a Nasdaq Hearings Panel.
• Continue to explore strategic alternatives, including a sale, merger, or similar transaction, to maximize shareholder value.
• Continue to investigate additional sources of financing based on market conditions and business objectives.

Key Dates

Recommendation

The company faces severe challenges, including repeated Nasdaq non-compliance, the failure of a previous reverse stock split, and disclosed material weaknesses in internal controls. The need for another reverse stock split and a substantial increase in authorized shares (which carries significant dilution risk) indicates a precarious financial and operational position. While exploring strategic alternatives, the immediate outlook is negative due to delisting risk and fundamental issues. A seasoned investor would likely view these as strong indicators of underlying problems and recommend selling to avoid further potential losses.

Keywords

Movano Inc., MVNO, SEC filing, Proxy Statement, Annual Meeting, Reverse Stock Split, Nasdaq compliance, Authorized shares, Stockholder vote, Corporate governance, Director election, Auditor ratification, Capital raise, Dilution, Financial reporting, Internal controls, Stock price, Delisting, Strategic alternatives